USE, COSTS AND FACTORS ASSOCIATED WITH NON-INDICATED ANTI-REFLUX MEDICATION PRESCRIBING
Background: Prescribing of anti-reflux medications in children, particularly infants, has increased over recent decades, raising concern about non-indicated prescribing or low-value health care in this population. 1, 2 Little is known about factors associated with non-indicated prescribing in hospitals. Objectives: To (i) quantify indicated versus non-indicated prescribing of anti-reflux medications in a tertiary paediatric hospital; (ii) determine patient, provider and hospital factors associated with non-indicated prescribing and (iii) establish relative costs to the healthcare system of indicated versus non-indicated prescribing.
Methods: A prospective, 2-month electronic medical audit was conducted at The Royal Children's Hospital (RCH) Melbourne, across August-September 2016. Scripts written for proton pump inhibitors (PPIs) and histamine 2-receptor antagonists (H 2 RAs) were extracted, together with relevant patient, provider and hospital data including Inpatient, Outpatient and Emergency Department (ED) settings. Bivariate factor and logistic regression analyses of variables associated with indicated and non-indicated prescribing were undertaken. A costing study involved linking RCH 'unit' and PBS costs to Inpatient and Outpatient/ED scripts, respectively, summed to estimate indicated, non-indicated and total costs.
Results: Across all settings, there were more non-indicated than indicated prescriptions. Factors associated at the bivariate level (p < 0.05) with non-indicated prescribing included (i) the use of 'possible steroids' and (ii) the presence of gastrostomy (PEG/PEJ) for Inpatients and Outpatients. Having a predisposing diagnosis (e.g. congenital oesophageal defect, chronic neurological impairment) was associated with indicated prescribing for Inpatients ( 
